NASDAQ:QURE - Nasdaq - NL0010696654 - Common Stock - Currency: USD
12.84
-0.12 (-0.93%)
The current stock price of QURE is 12.84 USD. In the past month the price decreased by -18.89%. In the past year, price increased by 103.17%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 480 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
UNIQURE NV
Paasheuvelweg 25a
Amsterdam NOORD-HOLLAND 1105 BP NL
CEO: Matthew Kapusta
Employees: 480
Company Website: http://www.uniqure.com/
Investor Relations: https://www.uniqure.com/investors-media/
Phone: 31202406000
The current stock price of QURE is 12.84 USD. The price decreased by -0.93% in the last trading session.
The exchange symbol of UNIQURE NV is QURE and it is listed on the Nasdaq exchange.
QURE stock is listed on the Nasdaq exchange.
19 analysts have analysed QURE and the average price target is 36.91 USD. This implies a price increase of 187.43% is expected in the next year compared to the current price of 12.84. Check the UNIQURE NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
UNIQURE NV (QURE) has a market capitalization of 682.45M USD. This makes QURE a Small Cap stock.
UNIQURE NV (QURE) currently has 480 employees.
UNIQURE NV (QURE) has a support level at 12.83 and a resistance level at 14.19. Check the full technical report for a detailed analysis of QURE support and resistance levels.
The Revenue of UNIQURE NV (QURE) is expected to grow by 89.14% in the next year. Check the estimates tab for more information on the QURE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
QURE does not pay a dividend.
UNIQURE NV (QURE) will report earnings on 2025-03-03, after the market close.
UNIQURE NV (QURE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.96).
The outstanding short interest for UNIQURE NV (QURE) is 6.62% of its float. Check the ownership tab for more information on the QURE short interest.
ChartMill assigns a technical rating of 5 / 10 to QURE. When comparing the yearly performance of all stocks, QURE is one of the better performing stocks in the market, outperforming 97.88% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to QURE. QURE has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months QURE reported a non-GAAP Earnings per Share(EPS) of -4.96. The EPS decreased by -3.25% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -37.09% | ||
ROE | -429.05% | ||
Debt/Equity | 8.56 |
ChartMill assigns a Buy % Consensus number of 84% to QURE. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 35.76% and a revenue growth 89.14% for QURE